Last reviewed · How we verify

Topical treatment

Aresus Pharma GmbH · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Topical treatment is a Small molecule drug developed by Aresus Pharma GmbH. It is currently FDA-approved. Also known as: Veregen 10% ointment.

Topical treatments have been studied for various skin conditions, including atopic dermatitis and skin carcinoma, as well as for improving skin smoothness, radiance, and overall appearance. The treatments used in these studies include a biocellulose mask, post-procedure cream, and gentle cleanser, but the exact mechanism of action is currently unknown.

At a glance

Generic nameTopical treatment
Also known asVeregen 10% ointment
SponsorAresus Pharma GmbH
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topical treatment

What is Topical treatment?

Topical treatment is a Small molecule drug developed by Aresus Pharma GmbH.

Who makes Topical treatment?

Topical treatment is developed and marketed by Aresus Pharma GmbH (see full Aresus Pharma GmbH pipeline at /company/aresus-pharma-gmbh).

Is Topical treatment also known as anything else?

Topical treatment is also known as Veregen 10% ointment.

What development phase is Topical treatment in?

Topical treatment is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing